ArticleBlood advances2025
Progressive silent cerebral infarction is associated with stroke and persistent cognitive impairment in survivors of iTTP.
Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Solving another piece of the thrombotic thrombocytopenic purpura puzzle?Research and practice in thrombosis and haemostasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
abstractSurvivors of immune thrombotic thrombocytopenic purpura (iTTP) face an increased risk of cerebrovascular disease, including silent cerebral infarction (SCI), cognitive impairment, and stroke. The prospective Neurologic Sequelae of iTTP study evaluated the natural history of SCI (by brain magnetic resonance imaging) during clinical remission and its association with stroke risk and cognitive impairment, measured by the National Institutes of Health Toolbox cognition battery. SCI burden was quantified using the modified age-related white matter changes (ARWMC) score. Among 42 patients who completed the baseline study visit, 28 completed a second assessment at a median interval of 12.5 months. New or progressive SCI were observed in 8 of 28 patients (28.6%), with the median ARWMC score increasing from 4 to 5 (P = .002). SCI progression was associated with a higher baseline ARWMC score (median, 7 vs 1; P = .011) but not with age, hypertension, diabetes, or average remission ADAMTS13 activity. Over a median follow-up of 32 months, 6 of 42 participants (14.3%) developed stroke, with significantly higher stroke risk among those with a higher baseline ARWMC score (hazard ratio, 1.36; 95% confidence interval, 1.01-1.83; P = .043). Cognitive function significantly improved in patients without SCI progression but not in those with progressive SCI. In summary, SCI is progressive during clinical remission in iTTP and associated with an increased risk of stroke and persistent cognitive impairment. SCI burden and progression may serve as shorter-term end points for clinical trials aimed at mitigating stroke risk and improving cognitive outcomes after iTTP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.